## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the Application:

## 1. (Original) A compound of formula Ia:

$$R_1$$
 $R_1$ 
 $R_2$ 
 $R_3$ 

(Ia)

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

 $R_1$  is  $CO_2R_4$ ;

each  $R_2$  is independently -halo, -NO<sub>2</sub>, -CN, -OH, -N( $R_5$ )( $R_5$ ), -OR<sub>5</sub>, -C(O)R<sub>5</sub>, -OC(O)R<sub>5</sub>, -C(O)NHC(O)R<sub>5</sub>, -(C<sub>1</sub>-C<sub>10</sub>)alkyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl, -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>5</sub>-C<sub>10</sub>)cycloalkenyl, -(C<sub>3</sub>-C<sub>10</sub>)heterocycle, -phenyl, -naphthyl, -benzyl, -CO<sub>2</sub>R<sub>5</sub>, -C(O)OCH( $R_5$ )( $R_5$ ), -NHC(O)R<sub>5</sub>, -NHC(O)NHR<sub>5</sub>, -C(O)NHR<sub>5</sub>, -OC(O)R<sub>5</sub>, -OC(O)OR<sub>5</sub>, -SR<sub>5</sub>, -S(O)R<sub>5</sub>, or -S(O)<sub>2</sub>R<sub>5</sub>;

 $R_{3} \text{ is -H, -halo, -NO}_{2}, -CN, -OH, -N(R_{5})(R_{5}), -O(CH_{2})_{m}R_{5}, -C(O)R_{5}, -C(O)NR_{5}R_{5},\\ -C(O)NH(CH_{2})_{m}(R_{5}), -OCF_{3}, -benzyl, -CO_{2}CH(R_{5})(R_{5}), -(C_{1}-C_{10})alkyl, -(C_{2}-C_{10})alkenyl,\\ -(C_{2}-C_{10})alkynyl, -(C_{3}-C_{10})cycloalkyl, -(C_{8}-C_{14})bicycloalkyl, -(C_{5}-C_{10})cycloalkenyl, -naphthyl,\\ -(C_{3}-C_{10})heterocycle, -CO_{2}(CH_{2})_{m}R_{5}, -NHC(O)R_{5}, -N(R_{5})C(O)R_{5}, -NHC(O)NHR_{5},\\ -OC(O)(CH_{2})_{m}CHR_{5}R_{5}, -CO_{2}(CH_{2})_{m}CHR_{5}R_{5}, -OC(O)OR_{5}, -SR_{5}, -S(O)_{2}R_{5},\\ -S(O)_{2}NHR_{5}, or$ 

$$(R_6)_p$$
 ;

 $R_4$  is -( $C_5$ )heteroaryl, -( $C_6$ )heteroaryl, phenyl, naphthyl, or benzyl;

each  $R_5$  is independently -H, -CF<sub>3</sub>, -( $C_1$ - $C_{10}$ )alkyl, -benzyl, -adamantyl, -morpholinyl, -pyrrolidyl, -pyrrolidyl, -pyrrolidinyldione, -piperdidyl, -( $C_2$ - $C_{10}$ )alkenyl, -( $C_2$ - $C_{10}$ )alkynyl, -( $C_3$ - $C_{10}$ )cycloalkyl, -( $C_8$ - $C_{14}$ )bicycloalkyl, -( $C_3$ - $C_{10}$ )heterocycle, or

$$-(R_{\theta})_{p}$$
;

each R<sub>6</sub> is independently -H, -halo, -NO<sub>2</sub>, -CN, -OH, -CO<sub>2</sub>H,

- $-N((C_1-C_{10})alkyl))((C_1-C_{10})alkyl)$ ,  $-O(C_1-C_{10})alkyl$ ,  $-C(O)(C_1-C_{10})alkyl$ ,
- $-C(O)NH(CH_2)_m(C_1-C_{10})alkyl, -OCF_3, -benzyl, -CO_2(CH_2)_mCH((C_1-C_{10})alkyl)((C_1-C_{10})alkyl), -CO_2(CH_2)_mCH((C_1-C_{10})alkyl), -CO_2(CH_2)_mCH((C_1-C_1)_alkyl), -CO_2(CH_2$
- -C(O)H,  $-CO_2(C_1-C_{10})$  alkyl,  $-(C_1-C_{10})$  alkyl,  $-(C_2-C_{10})$  alkenyl,  $-(C_2-C_{10})$  alkynyl,
- -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl, -(C<sub>5</sub>-C<sub>10</sub>)cycloalkenyl, -(C<sub>5</sub>)heteroaryl,
- -( $C_6$ )heteroaryl, -phenyl, naphthyl, -( $C_3$ - $C_{10}$ )heterocycle, - $CO_2$ ( $CH_2$ )<sub>m</sub>( $C_1$ - $C_{10}$ )alkyl,
- $-CO_2(CH_2)_mH$ ,  $-NHC(O)(C_1-C_{10})$  alkyl,  $-NHC(O)NH(C_1-C_{10})$  alkyl,  $-OC(O)(C_1-C_{10})$  alkyl,
- $-OC(O)O(C_1-C_{10})$  alkyl,  $-SO_2NHR_5$ , or  $-SO_2NH_2$ ;

n is an integer ranging from 0 to 4;

each m is independently an integer ranging from 0 to 8; and

each p is independently an integer ranging from 0 to 5.

2. (Original) A pharmaceutical composition comprising an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt or hydrate thereof and a pharmaceutically acceptable carrier or excipient.

Claims 3-13 have been canceled without prejudice.

14. (Original) A compound of formula (Ib):

(Ib)

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

 $R_1$  is -H, -CO<sub>2</sub>R<sub>4</sub>, -C(O)R<sub>5</sub>, or -C(O)N(R<sub>5</sub>)(R<sub>5</sub>);

 $R_2 \text{ is -}(C_1\text{-}C_{10}) \text{alkyl or -}O(C_1\text{-}C_{10}) \text{alkyl;}$   $R_4 \text{ is -}(C_5) \text{heteroaryl, -}(C_6) \text{heteroaryl, phenyl, naphthyl, or benzyl; and}$  each occurrence of  $R_5$  is independently -H, -CF<sub>3</sub>, -(C<sub>1</sub>-C<sub>10</sub>) alkyl, -benzyl, -(C<sub>2</sub>-C<sub>10</sub>) alkenyl, -(C<sub>2</sub>-C<sub>10</sub>) alkynyl, -(C<sub>3</sub>-C<sub>10</sub>) cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>) bicycloalkyl, or -(C<sub>3</sub>-C<sub>10</sub>) heterocycle.

Claims 15-25 have been canceled without prejudice.

- 26. (Previously Presented) A pharmaceutical composition comprising an effective amount of a compound of claim 14 or a pharmaceutically acceptable salt or hydrate thereof and a pharmaceutically acceptable carrier or excipient.
- 27. (New) The compound or pharmaceutically acceptable salt or hydrate of claim 14, wherein  $R_1$  is -H.